SCHEMBL15280907

SCHEMBL15280907

CC(C)(C)C[C@H]1O[C@@H](n2ccc(N)nc2=O)CC1OP(=O)(O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.49
POLG P54098 2/20 0.45
P2RY2 P41231 4/20 0.44
P2RY4 P51582 3/20 0.44
P2RY6 Q15077 2/20 0.44
LMNA P02545 3/20 0.41
PDE3A Q14432 3/20 0.41
CACNA1F O60840 2/20 0.41
ALB P02768 2/20 0.41
MAPT P10636 2/20 0.41
CACNA1D Q01668 2/20 0.41
CACNA1S Q13698 2/20 0.41
CACNA1C Q13936 2/20 0.41
NT5E P21589 1/20 0.38
POLA1 P09884 1/20 0.38
THRB P10828 1/20 0.38
MTOR P42345 1/20 0.38
MDM2 Q00987 1/20 0.38
NCOA1 Q15788 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24784384 1.00 POLB (0.49) POLBPOLGP2RY2P2RY4P2RY6
SCHEMBL15280768 1.00 POLB (0.49) POLBPOLGP2RY2P2RY4P2RY6
SCHEMBL19887009 0.93 POLB (0.47) POLBPOLGP2RY2P2RY4P2RY6
SCHEMBL15280801 0.93 POLB (0.47) POLBPOLGP2RY2P2RY4P2RY6
SCHEMBL22292271 0.87 POLB (0.46) POLBPOLGP2RY2P2RY4P2RY6
SCHEMBL19887004 0.85 TK1 (0.38) POLBPOLG
SCHEMBL15280861 0.85 TK1 (0.38) POLBPOLG
SCHEMBL15280754 0.84 POLB (0.46) POLBPOLGP2RY2P2RY4P2RY6
SCHEMBL19887010 0.84 POLB (0.46) POLBPOLGP2RY2P2RY4P2RY6
SCHEMBL25070784 0.83 POLB (0.55) POLBPOLGP2RY2P2RY4P2RY6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200172903-A1 ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION OSAKA UNIVERSITY (JP) 2020-06-04 US disclosed
US-9803199-B2 Cationic lipid DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-10-31 US disclosed
US-20160257951-A1 NOVEL LIPID DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-09-08 US disclosed
US-8987226-B2 Modified single-stranded polynucleotides DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-03-24 US disclosed
US-20130253038-A1 Modified Single-Stranded Polynucleotide DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160257951-A1 NOVEL LIPID NPC1L1, CETP, LIPC POLB 394/4885POLG 599/4885P2RY2 2117/4885
US-20200172903-A1 ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION SNCA, ENO1, ENY2 POLB 89/4885POLG 442/4885P2RY2 2184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.